Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9Y5Q3
UPID:
MAFB_HUMAN
Alternative names:
V-maf musculoaponeurotic fibrosarcoma oncogene homolog B
Alternative UPACC:
Q9Y5Q3; B3KNE1; Q9H1F1
Background:
Transcription factor MafB, known as V-maf musculoaponeurotic fibrosarcoma oncogene homolog B, plays a critical role in lineage-specific hematopoiesis, influencing cell fate in myeloid cells, macrophages, osteoclasts, podocytes, and islet beta cells. Its regulatory functions extend to activating insulin and glucagon promoters, with SUMO modification modulating its transcriptional activity.
Therapeutic significance:
MafB's involvement in Multicentric carpotarsal osteolysis syndrome and Duane retraction syndrome 3 highlights its potential as a therapeutic target. Understanding the role of Transcription factor MafB could open doors to potential therapeutic strategies for these conditions.